Managing Drug Safety Challenges from Clinical Trials to Post Marketing Stages
with Sundos Hamza, M.D., Senior Vice President, Drug Safety Risk Management, InterMune
Amid Zand Interview Dr. Sundos Hamza of InterMune on December 12, 2014. In this interview Dr. Hamza speaks about the importance of effective global drug safety risk minimization strategies in clinical and post marketing phases of drug development.
Topics Include: Drug Safety Risk Minimization, Streamlined drug safety process, safety signals, global Safety issues, post marketing safety surveillance and clinical to post marketing transition
Effective Patient Engagement and Education for Clinical Trials Recruitment and Retention
with Nariman Nasser, Digital Strategist, Genentech
Amid Zand Interview Ms. Nariman Nasser of Genentech, on December 23, 2014. Nariman will be speaking at the SCOPE Summit in Orlando, FL in a track titled managing late stage research, observational studies and registries. Her talk will focus on digital strategies that makes observational studies more accessible and better aligned with patients lives.
Topics Include: Late Stage Clinical Research, Patient Engagement, Clinical Trial Enrollment, Patient education, Clinical Trial advertising and Digital recruitment and retention
“Sci-Fi Come to Life”: Improving Translational and Drug Research with Tissue and Organ Chips
with Kristin Fabre, Ph.D., Scientific Program Manager, NCATS, National Institutes of Health
CHI interviewed Dr. Kristin Fabre of NCATS at the National Institutes of Health speaks to CHI on September 3, 2014. Dr. Fabre will be a keynote speaker during the Engineering Functional 3D Models and Organotypic Culture Models for Toxicology conferences at the FAST Congress, November 17-19 in Boston, MA.
Topics include NCATS’s Tissue Chip for Drug Screening Program, increased government support for tissue and organ chips, the benefits of these models for drug research, opening the drug discovery bottleneck through human surrogate technology and more.
Human Reference Genome Assembly Changes: Impact on Research and Interpretation of Results
with Valerie A. Schneider, Ph.D., Staff Scientist, National Center for Biotechnology Information, National Library of Medicine, National Institutes of Health
An-Dinh Nguyen interviews Valerie A. Schneider of the National Center for Biotechnology Information (NCBI), NIH on April 4, 2014. Dr. Schneider will be a speaker at TCGC: The Clinical Genome Conference, June 10-12, 2014 in San Francisco, CA.
Updates to the human reference genome assembly, the Genome Reference Consortium (GRC), the relationship of the assembly to annotation and genome browsers, new assembly features and their potential impact on clinical analyses and interpretation of results.
Insights into Optimizing the Impact of Academic-Industry Alliances: Discussing Past, Present and Future Trends, Challenges and Opportunities
with Dr. Teri Melese, Associate Professor of Medicine, and Assistant Vice Chancellor of Industry Alliances at the University of California, San Diego shares insights into the evolution, challenges, opportunities, and outlook for academic-industry partnerships
Dr. Melese will be moderating a discussion on this topic during the 11th Annual Strategic Alliance Management Congress, taking place, May 5-7, 2014 in Philadelphia. She'll be joined by a notable panel of the industry's best, including Anthony Marshall of IBM, Sylvaine Cases of Sanofi-Aventis, Noah Leibowitz of Simpson Thacher & Bartlett, and Yvonne Tran of Schrödinger.
What changes have been noted with these types of partnerships over the past decade?
What challenges exist that are harder to overcome? What are clear-cut and feasible opportunities?
What will the panel discussion Optimizing the Impact of Academic-Industry Alliances on Innovation convey to attendees during the 11th Annual Strategic Alliance Congress?
What is the outlook for the ways in which these partnerships will continue to evolve? What does this mean for stakeholders involved?
Translation of Genomic Data, Computational Biology and Biological Complexity
with David Galas, Ph.D., Principal Scientist, Pacific Northwest Diabetes Research Institute
An-Dinh Nguyen interviews David Galas of Pacific Northwest Diabetes Research Institute on March 27, 2014. Dr. Galas will be a keynote speaker at TCGC: The Clinical Genome Conference, June 10-12, 2014 in San Francisco, CA.
The challenges of translating genomic data into diagnostics and therapeutics, the promise of computational biology approaches for overcoming those barriers, the possible impact of extracellular RNA and the microbiome on human biology and more.
The Future of Fragments and PPIs
with Daniel A. Erlanson, Ph.D., Co-Founder, Carmot Therapeutics, Inc. and Edward R. Zartler, Ph.D., President & CSO, Quantum Tessera Consulting
Dr. Erlanson of Carmot Therapeutics and Dr. Zartler of Tessera Consulting speak with CHI's Dr. Shah on March 14, 2014 about new strategies for fragment linking, different companies' fragment-based campaigns, and types of PPI-directed compounds advancing in the clinic.
Dr. Erlanson will be speaking at the Fragment Based Drug Discovery meeting on April 24-25, 2014 in San Diego, part of CHI's Drug Discovery Chemistry event about Fishing for Fragments to Complement Known Binders.
Dr. Zartler was the scientific advisor to Dr. Shah for the Protein-Protein Interactions meeting taking place April 23-24, 2014 in San Diego, part of CHI's Drug Discovery Chemistry event.
Drs. Erlanson and Zartler are also co-instructors of one of the dinner workshops at the event, Advancing Tools and Technologies for Fragment-Based Design on April 24, 2014.
Erlanson and Zartler are also co-editors of the Practical Fragments blog: Click Here
In vivo Selection of Antibodies
with Luis Álvarez-Vallina, M.D., Ph.D., Associate Professor, Department of Engineering - BCE Protein Engineering, Aarhus University
Christina Lingham interviews on Luis Álvarez-Vallina of Aarhus University on March 27, 2014. Dr. Álvarez-Vallina will be speaking at the Phage and Yeast Display track at PEGS, on May 5-6 in Boston, Mass.
Phage display, in vivo selection of antibodies. tumor targeting, novel tumor-associated antigens, antibody-based therapeutics, targeted delivery.
Structures, Chemical Probes, New Biology, New Targets for Drug Discovery: Is This the Right Sequence?
with Chas Bountra, Ph.D., Professor, Translational Medicine; Head, Structural Genomics Consortium, University of Oxford
CHI recently spoke with Dr. Chas Bountra, Head of the Structural Genomics Consortium (SGC), and Professor of Translational Medicine and an Associate Head of Medical Sciences at the University of Oxford. In this podcast, Dr. Bountra discusses how the SGC is impacting drug discovery and their work on developing novel probes, specifically for epigenetic targets. Dr. Bountra also gives a sneak peek into his keynote lecture joining the Structure-Based Drug Design and Chemical Biology for Target Validation meetings, May 22 in Boston.
Cloud Computing, Genomic Data Analysis and Clinical Validation
with Benjamin Breton, Bioinformatics Software Engineer, Good Start Genetics
R. Mark Adams, Ph.D., CIO, Good Start Genetics
An-Dinh Nguyen interviews Benjamin Breton and Mark Adams of Good Start Genetics on March 7, 2014. Mr. Breton and Dr. Adams will be co-instructing the pre-conference workshop, An Embarrassment of Riches: Choosing and Implementing Cloud Infrastructure to Replace On-Premises HPC for Next-Generation Sequence Analysis, and Dr. Adams will be speaking during a shared session for the Cloud Computing and Data Security meetings at Bio-IT World Conference & Expo 2014, April 29-May 1 in Boston, MA.
Optimizing genome sequencing data projects via cloud-based computing, the evolution of commercial bioinformatics efforts that manage genomic and genetic data, challenges ranging from systems integration to legal and regulatory requirements in clinical settings and more.
Epigenetic Inhibitors: Discovery to Clinic - A Medicinal Chemist's Perspective
with Dr. Matthew Fuchter, Senior Lecturer of Synthetic and Medicinal Chemistry at the Imperial College London
Kip Harry, Conference Director at Cambridge Healthtech Institute discusses epigenetic drug discovery with Dr. Matthew Fuchter, Senior Lecturer of Synthetic and Medicinal Chemistry at the Imperial College London.
- From an inhibitor development standpoint, what methods do you use for discovery to lead?
- Why do you choose natural products to aid in targeting epigenetic modifiers and is there limited chemical matter in this space?
- What opportunities are there for infectious disease and other indications?
- What has ignited all this interest in developing second generation epigenetic inhibitors – particularly targeting Histone Methyltransferases, Demethylases and BET Bromodomains?
- Have we learned anything from approved compounds?
- What are major challenges seen in the development of novel epigenetic inhibitors?
- What about safety and toxicity of compounds – is this a major concern?
- What talks/topics are you looking forward to during the Epigenetic Inhibitor Discovery Meeting?
- How quickly can we expect to see these novel medicines reaching patients in need?
- Is combination therapy where we will see the greatest impact in this space?
- Some compare the epigenetic enzymes to kinases, where they will provide years of fertile grounds for discovery. What do you think?
Novel Engineering Solutions for Potent Bispecific Antibodies
with Robert Mabry, Ph.D., Associate Director, Antibody Discovery and Bispecific Engineering, Adimab LLC
Christina Lingham interviews Robert Mabry of Adimab on March 25, 2014. Dr. Mabry will be speaking at the Engineering Bispecific Antibodies track at PEGS, on May 8-9 in Boston, Mass.
Common issues and engineering solutions for engineering bispecific antibodies, emerging applications for bispecifics and the growth of bispecific platforms currently under development.
Chemical Route Development of HCV Protease-Inhibitor, Telaprevir
with Dr. Gerald Tanoury
Dr. Gerald Tanoury from Vertex, featured speaker at CHI's 'Efficient Process Chemistry' meeting May 22-24, 2014 in Boston, speaks about dealing with two challenging chemical steps in the scale-up of HCV protease inhibitor, Telaprevir, which was launched in 2011 as a new treatment for hepatitis C infection. Tanoury also discusses Telaprevir's route development in the context of his views on what makes an efficient route and shares with the interviewer, Dr. Anjani Shah, Conference Director for CHI, what he is interested in learning more about at the meeting.
Smart Strategies for Developing Bispecifics, Combinations and Mixture of Antibodies
with Rakesh Dixit, Ph.D., DABT, Vice President, R&D, MedImmune (AstraZeneca Biologics)
Christina Lingham interviews Rakesh Dixit of MedImmune on March 26, 2014. Dr. Dixit will be speaking at the Advancing Bispecific Antibodies to the Clinic for Oncology track at PEGS, on May 7-8 in Boston, Mass.
Bispecific antibodies for oncology, engineering innovations for engineering bispecific antibodies, and bispecific platforms currently under development.
Executive Interview with BMS: Physicochemical Properties in Designing Better Drug Candidates to Ensure Compound Success
with Nicholas Meanwell, Ph.D., Executive Director, Department of Chemistry, Research and Development, Bristol-Myers Squibb Co.
Nandini Kashyap interviews Dr. Nicholas Meanwell, Executive Director of Department of Chemistry at Bristol-Myers Squibb Co. on March 25, 2014. Dr. Meanwell will be delivering keynote presentation during the 3rd Annual Property-Based Drug Design, May 22-23, 2014 at Westin Boston Waterfront Hotel in Boston, MA.
Physicochemical properties in drug discovery and development, Bio-physical properties, Property based drug design, drug design, Solid State properties, Solubility, Permeability, Lipophilicity, Physicochemical descriptors, High-Throughput Physicochemical Screens, Developability of molecules, Polymorphism, Discovery workflow
How HIGH Can You Get? Using in vitro Data to Reduce Animal Experiments & Enabling Forms in Discovery-Development Interface
with Geeti Gangal, Ph.D., Principal Scientist, Chemical and Pharmaceutical Profiling, Novartis Institutes for Biomedical Research, Inc.
Nandini Kashyap interviews Dr. Geeti Gangal of Novartis Institutes for Biomedical Research on March 26, 2014. Dr. Gangal will be speaking during the 2nd Annual Formulation and Drug Delivery conference which is taking place on May 21-22, 2014 as part of World Pharma Congress in Boston, MA
Poor Solubility, Bioavailability, Oral Drug delivery, Preclinical animal models, Drug Absorption, Dissolution Prediction and Experimentation, Discovery and development interface, Solubilization, Formulation material science, Enabling formulation, Enabling technologies, Nanotechnology, Characterization, Drug and Product stability, In vitro-In vivo correlation (IVIVC)
Development of Poorly Soluble Drug: Current and Future Perspectives on Dissolution Prediction and Experimentation
with Robert A. Bellantone, Ph.D., Associate Professor, Division of Pharmaceutical Sciences, Arnold & Marie Schwartz College of Pharmacy and Health Sciences, Long Island University; President, Physical Pharmaceutical LLC
Nandini Kashyap interviews Dr. Robert A. Bellantone of Long Island University on February 17, 2014. Dr. Bellantone will be speaking during the 2nd Annual Formulation and Drug Delivery conference taking place May 21-22, 2014 as part of World Pharma Congress in Boston, MA
Poor Solubility, Bioavailability, Oral Drug delivery, Solubilization, Formulation material science, Solid state characterization, Dissolution Prediction and Experimentation, Drug and Product stability, Drug form stability, In vitro-In vivo correlation (IVIVC), Excipient-water interaction, Excipient drug interaction
Exploring and Optimizing Cost-Effective Route toward DPP-IV Inhibitor Compounds
with Nhut Diep, Ph.D. Principal Scientist, Chemical Development, Forest Laboratories
Anjani Shah, Ph.D., Conference Director, Cambridge Healthtech Institute, interviews Dr. Nhut Diep of Forest Laboratories on February 19, 2014. Dr. Diep will be speaking during the 7th Annual 'Efficient Process Chemistry' conference taking place May 22-23, 2014 as part of CHI's World Pharma Congress May 21-23 in Boston, MA.
Efforts to identify a scalable process for preparing DPP-IV inhibitor compounds (diabetes therapeutic) led to the discovery of several useful transformations, including the asymmetric lithiation-boronation of the Boc-pyrrolidine that provided a single compound; the development of a streamline-telescope coupling reaction and workup which led to a robust crystallization/purification method.
Computational Modeling for CNS Drug Research and Clinical Trial Design
Hugo Geerts, Ph.D., MBA, BA, CSO, In Silico Biosciences; Adjunct Associate Professor, Perelman School of Medicine, University of Pennsylvania
An-Dinh Nguyen interviews Hugo Geerts of In Silico Biosciences and University of Pennsylvania on February 7, 2014. Dr. Geerts will be a speaker during the Systems Pharmacology conference at Bio-IT World Conference & Expo 2014, April 29-May 1 in Boston, MA.
Topics include the limitations of translating outcomes from models for clinical utility, the application of computer-based methods to pharmaceutical R&D to improve predictability of clinical trials, the complexities of researching and developing drug therapies for the central nervous system and more.
Software as a Service: Large-Scale Data Management for Reproducible Life Science Research
Ravi K. Madduri, Fellow, Computation Institute, University of Chicago; Project Manager, Mathematics and Computer Science Division, Argonne National Laboratory
An-Dinh Nguyen interviews Ravi Madduri of University of Chicago and Argonne National Laboratory on February 10, 2014. Mr. Madduri will be a speaker during the shared session for the Cloud Computing and Next-Gen Sequencing Informatics meetings at Bio-IT World Conference & Expo 2014, April 29-May 1 in Boston, MA.
Topics include the improvement of large-scale NGS analysis on the cloud, data management challenges life science researchers face, strategies and technologies for increasing scientists’ productivity and more.
Research and Risk: Data Sharing and Security for Pharma and Life Science
William Telford, Director, R&D IS Security, Sanofi R&D
An-Dinh Nguyen interviews William Telford of Sanofi on February 14, 2014. Mr. Telford will be a speaker during the shared session for the Data Security, IT Infrastructure – Hardware and Software Development meetings at Bio-IT World Conference & Expo 2014, April 29-May 1 in Boston, MA.
Topics include the evolution of data security strategies for pharmaceutical companies and life science collaborators, data classification to determine risk levels and protections, security challenges unique to the pharma industry and more.
Identifying Functional Elements of the Human Genome through Bioinformatics and Extremes
Christopher Mason, Ph.D., Assistant Professor, Computational Biomedicine, Weill Cornell Medical College
An-Dinh Nguyen interviews Christopher Mason of Weill Cornell Medical College on February 21, 2014. Dr. Mason will be speaking during the Clinical Genomics meeting at Bio-IT World Conference & Expo 2014, April 29-May 1 in Boston, MA.
Topics include the use of bioinformatics methods in genomics to study diseases, researching the human genome’s functional elements through aggressive tumors and other extreme cases, applying an evolutionary perspective and more.
Systems Pharmacology Approaches for Drug and Cancer Research
Avi Ma’ayan, Ph.D., Associate Professor, Pharmacology and Systems Therapeutics, Icahn School of Medicine at Mount Sinai
An-Dinh Nguyen interviews Avi Ma’ayan of Icahn School of Medicine at Mount Sinai on February 20, 2014. Dr. Ma’ayan will be a featured speaker during the shared session for the Systems Pharmacology and Cancer Informatics meetings at Bio-IT World Conference & Expo 2014, April 29-May 1 in Boston, MA.
Topics include the emergence of systems biology in drug research, promising datasets that can accelerate drug discovery and personalized medicine, methods for extracting knowledge from data, the potential research impact of systems pharmacology and more.
Emerging Drying Technologies: Room Temperature Stable Flu Vaccine Formulation Using Spray Drying
with Jeffrey Breit, Ph.D., Director, Pharmaceutical, Bend Research
Nandini Kashyap interviews Jeffrey Breit, Ph.D of Bend Research on November 15, 2013. Dr. Breit will be speaking during the Lyophilization and Emerging Drying Technologies conference at the PepTalk, January 13-17 in Palm Springs, CA.
Topics include using a vaccine formulation development, room temperature stability, use of spray drying, emerging drying technologies
Using Structure and Property-Based Methods to Create a Quality ITK Inhibitor
with Jason Burch, Ph.D., Scientist, Medicinal Chemistry, Genentech
This May 21-22 at the Structure-Based Drug Design conference in Boston, Dr. Jason Burch, a Medicinal Chemist at Genentech will give a talk on structure-based design and property optimization of potent and selective pyrazole carboxamide interleukin-2 inducible t-cell kinase (itk) inhibitors for the treatment of inflammatory diseases. CHI recently spoke with Dr. Burch about why he chose to pursue ITK inhibitors, important considerations for developing these types of inhibitors, and what techniques were used to improve pharmaceutical properties of the lead matter. Dr. Burch also discusses how advances in genomics and demand for personalized treatments has changed drug design techniques.
Unfolded Protein Response: Pathways to Recombinant Protein Production
with Zhimei Du, Ph.D., Senior Scientist, Cell Sciences & Technology, Amgen, Inc.
An-Dinh Nguyen interviews Zhimei Du of Amgen on November 1, 2013. Dr. Du will be speaking during the Recombinant Protein Expression and Production conference at PepTalk 2014, January 13-17 in Palm Springs, CA.
Topics include unfolded protein response, pathways for increasing recombinant protein production and expression yield, understanding cell status, UPR’s dynamic nature and cell line development at Amgen.
Cellular Biology, Biotechnology and Recombinant Protein Production
with Sabine Geisse, Ph.D., Director/NLS, Novartis Institutes for BioMedical Research
An-Dinh Nguyen interviews Sabine Geisse, Ph.D., Director/NLS, Novartis Institutes for BioMedical Research on October 31, 2013. Dr. Geisse will be a keynote speaker during the Transient Protein Production conference at PepTalk 2014, January 13-17 in Palm Springs, CA.
Topics include the importance of considering cellular environments when working on genes and molecular biology, the evolution of biotechnology, recombinant production of increasingly complex biomolecules and more.
Efficient Protein Expression and Engineered Bacteria
with Joseph Kittle, Jr., Ph.D., Assistant Professor, Chemistry and Biochemistry, Ohio University and CSO, Molecular Technologies Laboratories, LLC
An-Dinh Nguyen interviews Joseph Kittle of Ohio University and Molecular Technologies Laboratories, LLC on October 30, 2013. Dr. Kittle will be a speaker during the Engineering Genes, Vectors, Constructs and Clones conference at PepTalk 2014, January 13-17 in Palm Springs, CA.
Topics include problems with plasma-based protein expression, using engineered bacteria and chromosomally inserted genes, integrating current biotech industry knowledge with academic biochemistry and molecular engineering instruction and more.
Simplifying Genomics and Optimizing Protein Expression
with Curtis Knox, Vice President, Marketing & Sales, Lucigen Corp.
An-Dinh Nguyen interviews Curtis Knox of Lucigen on October 14, 2013. Mr. Knox will be a speaker during the
Engineering Genes, Vectors, Constructs and Clones conference at PepTalk 2014, January 13-17 in Palm Springs, CA.
Topics include the challenges and advantages of endotoxin reduction in recombinant protein expression processes for drug discovery R&D, high-throughput cloning and expression of target proteins, large insert metagenomic libraries from soil microbes and more.
Protein Expression and Biological Engineering: Bacteria and Beyond
with Sriram Kosuri, Ph.D., Assistant Professor, Chemistry and Biochemistry, University of California, Los Angeles
An-Dinh Nguyen interviews Sriram Kosuri of UCLA on November 11, 2013. Dr. Kosuri will be a keynote speaker during the Engineering Genes, Vectors, Constructs and Clones conference at PepTalk 2014, January 13-17 in Palm Springs, CA.
Topics include the effect of codon usage on protein expression, the reliance on bacteria for biological engineering research, new tools like CRISPR for studying more eukaryotic systems, next-generation gene synthesis, work at the Wyss Institute and more.
Protein Aggregation and Emerging Tools: Mechanism, Challenges, and Future Perspectives
with Thomas Laue, Ph.D., Professor, Biochemistry and Molecular Biology; Director, Biomolecular Interaction Technologies Center (BITC), University of New Hampshire
Nandini Kashyap interviews Prof. Thomas Laue of University of New Hampshire on November 19, 2013. Prof. Laue will be speaking during the Protein Aggregation and Emerging Analytical Tools conference at the PepTalk, January 13-17 in Palm Springs, CA.
Topics include protein aggregation, mechanism of protein aggregation, non-covalent interactions, hydrophobic effect, dipole-dipole interactions, effect of viscosity, development of analytical tools for aggregate detection, progress in the field of protein aggregation.
BPOG’s Extractable Protocol Standardization Journey: Update on E&L Collaboration Efforts Between BPOG and Major Industry Groups
with Ken Wong, Ph.D., Deputy Director, MTech, Sanofi Pasteur
Mimi Langley interviews Ken Wong, Ph.D., Deputy Director, MTech of Sanofi Pasteur on November 22, 2013. Dr. Wong will be speaking during the Single-Use Technologies & Continuous Processing in Biopharm Manufacturing conference at PepTalk, January 13-17 in Palm Springs, CA.
Topics include what are the current challenges on E&L, how are industry groups collaborating on this issue, and what are BPOG’s (Biophorum Operations Group) initiatives and efforts on standardization protocol.
IT Infrastructures for Genomic Data Management and Clinical Practice
with Niklas Blomberg, Ph.D., ELIXIR Director, ELIXIR Hub, EMBL-EBI, United Kingdom
An-Dinh Nguyen interviews Niklas Blomberg of ELIXIR on 7 October 2013. Dr. Blomberg will be a keynote speaker during the High-Scale Computing conference at the Clinical Genomics & Informatics Europe Conference & Expo on 4-6 December, in Lisbon, Portugal.
- Bioinformatics for Managing Large Data Volumes
- Sustainable IT Infrastructures for Life Science Research and Clinical Practice
- Advances in IT Infrastructures for Genomic Data Management and Analysis
- ELIXIR’s Mission, Considerations and Challenges
Public Health Genomics, Data and Ethics
with Anne Cambon-Thomsen, M.D., Director, Research, Centre National de la Recherche Scientifique (CNRS), France
An-Dinh Nguyen interviews Anne Cambon-Thomsen of CNRS on 23 October 2013. Dr. Cambon-Thomsen will be a keynote speaker during the Genome Informatics conference at the Clinical Genomics & Informatics Europe Conference & Expo on 4-6 December, in Lisbon, Portugal.
- Interdisciplinary Aspects of Public Health Research
- Ethical, Societal and Legal Issues
- Applications of Immunogenetics Research
- Genomic Data Sharing vs. Privacy Protection
Cloud Computing and Storage for Genomic Research and the Clinic
with Wolfgang Gentzsch, Ph.D., Co-Founder, The UberCloud HPC Experiment; Executive Consultant, HPC, Grid and Cloud; Advisor, EUDAT; Chairman, ISC Cloud Conferences, Germany
An-Dinh Nguyen interviews Wolfgang Gentzsch of The UberCloud HPC Experiment on 4 October 2013. Dr. Gentzsch will be speaking during the High-Scale Computing conference at the Clinical Genomics & Informatics Europe Conference & Expo on 4-6 December, in Lisbon, Portugal.
- Cloud Computing Services for R&D Scientists and Engineers via UberCloud
- Progress in Cloud Computing and Storage for Genomic Research and Clinical Practice
- Challenges: Security, Data Management, Software License Restrictions
- EUDAT’s Collaborative Data Infrastructure
Genetics and the Public: The Impact of Research
with Heidi Carmen Howard, Ph.D., Assistant Professor, Biomedical Ethics, IQ Healthcare, Radboud University Medical Centre, Netherlands and Senior Research Fellow, Département d’épidémiologie et de Santé Publique, INSERM, Faculté de Médecine, Université Toulouse, France
An-Dinh Nguyen interviews Heidi Carmen Howard of Radboud University Medical Centre and INSERM on 16 October 2013. Dr. Howard will be speaking during the Genome Informatics conference at the Clinical Genomics & Informatics Europe Conference & Expo on 4-6 December, in Lisbon, Portugal.
- The Translation of Genetic Data into the Clinic
- The Necessity of Ethical, Social and Legal Considerations in Genomics
- Genetics for Consumers, Patients and Public Health
Highlights from the Upcoming Clinical Exome Sequencing Conference
with Gholson J. Lyon, M.D., Ph.D., Assistant Professor of Human Genetics, Cold Spring Harbor Laboratory and Research Scientist, Utah Foundation for Biomedical Research, United States
Kip Harry interviews Gholson Lyon of the Cold Spring Harbor Laboratory on 13 September 2013. Dr. Lyon will be speaking during the Clinical Exome Sequencing conference at the Clinical Genomics & Informatics Europe Conference & Expo on 4-6 December, in Lisbon, Portugal.
- Biology and Targeting of Cancer through Exome Sequencing
- Technical Steps for Exome Sequencing
- Analyzing Exome Data
- Implementing Exome Sequencing in a Clinical Lab
- Comparing and Contrasting Exome vs. Whole Genome Sequencing
- Exome Sequencing Survey of Cancers
- Standardizing Library Prep and Intra-Patient Genomic Heterogeneity
- Exome Sequencing for Candidate Gene Discovery with Clinical Samples
The Importance of RNA-Sequencing: Advantages, Applications and Challenges
with David I. Smith, Ph.D., Professor, Department of Laboratory Medicine and Pathology, Mayo Clinic, United States and Melanie Lehman, Ph.D., Research Fellow, Australian Prostate Cancer Research Centre, Queensland University of Technology, Australia
Kip Harry interviews Dr. David Smith from the Mayo Clinic, and Dr. Melanie Lehman from Queensland University of Technology for the upcoming RNA-Seq and Transcriptome Analysis meeting, 5-6 December in Lisbon, Portugal.
Discussion points during the interview include:
- The advantages of using RNA-Seq for expression analysis over microarrays
- The impact of RNA-Seq on research and recent advances in the applications of this technology
- Ways in which RNA-Seq is being utilized clinically
- Current challenges/limitations with RNA-Seq
Genetic Analysis of Cancer: Computational and Collaborative Approaches
with Zoltan Szallasi, M.D., Senior Research Scientist, Children’s Hospital Informatics Program, Harvard Medical School, United States and Professor, Systems Biology, Danish Technical University, Denmark
An-Dinh Nguyen interviews Zoltan Szallasi of Harvard Medical School and Danish Technical University on 23 October 2013. Dr. Szallasi will be speaking during the Genome Informatics conference at the Clinical Genomics & Informatics Europe Conference & Expo on 4-6 December, in Lisbon, Portugal.
- Clinical Validation and Analysis of Cancer Genomic Data
- Computational and Experimental Methods for Detecting Genomic Instability
- Quantifying Homologous Recombination in Tumor Biopsies
- Platinum Sensitivity in Breast Cancer
- Adapting to Next-Generation Sequencing
Biospecimen Research and the Cohorts Biorepository
Sherilyn Sawyer, Ph.D., Scientific Director, BWH/Harvard Cohorts Biorepository, Channing Division of Network Medicine, Brigham and Women’s Hospital
An-Dinh Nguyen interviews Dr. Sawyer on September 10, 2013. She is a speaker for the Biospecimens and Translational Science session at the Leaders in Biobanking Congress, November 4-5, in Indianapolis, IN. Topics include the evolution of biospecimen collection and usage, biouser needs, future challenges and opportunities.
Sample Acquisition and Management: Biobanking Regulations and Improvements
Brian Chadwick, Managing Member and Consultant, LookLeft Group LLC
An-Dinh Nguyen interviews Mr. Chadwick of LookLeft Group LLC on September 10, 2013. He is a speaker for the Business of Running a Biobank session at the Leaders in Biobanking Congress, November 4-5, in Indianapolis, IN. Topics include regulatory compliance challenges of biospecimen management, software solutions, commercial vs. nonprofit biobanks, patient rights and more.
Biobanking and Biopreservation: The Promise, Problems and Solutions
Allison Hubel, Ph.D., Professor, Mechanical Engineering and Director, Biopreservation Core Resource, University of Minnesota
An-Dinh Nguyen interviews Dr. Hubel of the Biopreservation Core Resource at the University of Minnesota on September 5, 2013. She is a speaker for the Science of Supplying High-Quality Specimens session at the Leaders in Biobanking Congress, November 4-5, in Indianapolis, IN. Topics cover biobanking’s rising prominence, biospecimen collection and storage challenges, microfluidics applications for biopreservation and more.
Dr. Bruce Korf Discusses the Challenges, Opportunities and Most Important Developments in the Integration of Genomics and Medicine
Speaker: Bruce R. Korf, M.D., Ph.D., Wayne H. and Sara Crews Finley Chair in Medical Genetics; Professor and Chair, Department of Genetics; Director, Heflin Center for Genomic Sciences, University of Alabama at Birmingham
Dr. Ramesh Ramanathan Shares the Advantages and Best Practices for the Molecular Profiling of Tumors
Speaker: Ramesh Ramanathan, M.D., Medical Director, The Virginia G. Piper Cancer Center Clinical Trials
Regulatory and Manufacturing Considerations for Stem Cell Therapies Podcast
Speaker: Larry A. Couture, Ph.D., Senior Vice President, Center for Applied Technology Development, Beckman Research Institute of City of Hope
Genomic Screening and Diagnosis of Human Diseases Podcast
Speaker: Charles Cantor, Founder, Chief Scientific Officer, SEQUENOM, Inc.
PCR Technologies Podcast
Speaker: Carl Wittwer, M.D., Ph.D., Professor, Pathology, University of Utah
Enabling Physician Use of Genomic Data Through Cloud-Based Software
Speaker: Jonathan Hirsch, Founder & President, Syapse
Microfluidics for Mobile Diagnostics
Speaker: Samuel K. Sia, Associate Professor, Biomedical Engineering, Columbia University
Reducing & Monitoring Bioassay Variability
Janet L. Lathey, Ph.D., Director, Immunology and Assay Development, BioDefense Division,
Release Date: Aug 19, 2013
Genome in a Bottle
Marc Salit, Ph.D., Leader, Multiplexed Biomolecular Science Group, NIST Chemical Science and Technology Laboratory
Justin Zook, Ph.D., Multiplexed Biomolecular Science Group, NIST Chemical Science and Technology Laboratory
Release Date: Feb 12, 2013
Knowing your NGS Upstream: Alignment and Variant Callers
Gabe Rudy, Vice President, Product Development, Golden Helix
Release Date: Jan 2, 2013
Dr. Bruce Korf Discusses the Challenges, Opportunities and Most Important Developments in the Integration of Genomics and Medicine
Bruce R. Korf, M.D., Ph.D., Wayne H. and Sara Crews Finley Chair in Medical Genetics; Professor and Chair, Department of Genetics; Director, Heflin Center for Genomic Sciences, University of Alabama at Birmingham
Release Date: Nov 5, 2012
Dr. Ramesh Ramanathan Shares the Advantages and Best Practices for the Molecular Profiling of Tumors
Ramesh Ramanathan, M.D., Medical Director, The Virginia G. Piper Cancer Center Clinical Trials
Release Date: Nov 5, 2012
Folding in The Cloud
Vijay Pande, Ph.D., Professor, Chemistry, Structural Biology, Computer Science; Director, Biophysics Program; Director, Folding@home Distributed Computing Project
Release Date: Aug 6, 2012
Canonical Genes, Pseudogenes & ncRNA
Mark Gerstein, Ph.D., Albert L. Williams Professor of Biomedical Informatics, Molecular Biophysics and Biochemistry, Computer Science, Yale University
Release Date: Jul 23, 2012
Life in the Fast Lane - Genomes Race to the Cloud
Michael Sullivan, M.D., Associate Director, Health Sciences, Internet2
Stephen Simms, Manager, High Performance File Systems, Indiana University Pervasive Technology Institute
Release Date: Jul 17, 2012
Made in Manhattan: The Rapid Growth of the New York Genome Center
Nancy J. Kelley, J.D., M.P.P., Founding Executive Director, New York Genome Center
Release Date: Jul 17, 2012
Open Flow Tackles Network Automation and Programmability for Cloud Implementations
Isabelle Guis, Vice President, Outbound Marketing, Big Switch Networks
Release Date: Jul 12, 2012
POC: The Search for the Holy Grail Continues
Harry Glorikian, Founder and Managing Partner, Scientia Advisors LLC
Release Date: Jun 19, 2012
MALDI-TOF in the Mycobacteriology Laboratory
Nathan A. Ledeboer, Ph.D., Assistant Professor of Pathology, Medical College of Wisconsin
Release Date: Jun 13, 2012
Revolutionary Point-of-Care (POC) Diagnostic Technologies to Improve the Prevention, Control and Treatment of Infectious Diseases
Michel G. Bergeron, O.Q., M.D., FRCPC, Director and Founder, Centre de Recherche en Infectiologie de l'Université Laval
Release Date: May 10, 2012
Building a Genome Sequencing Center: Managing and Mining Two Years of NGS Data
Stuart Brown, Ph.D., Associate Professor, Center for Health Informatics & Bioinformatics, New York University School of Medicine
Release Date: Apr 28, 2012
Preparation of Nucleic Acid Libraries for Next-Generation Sequencers with an Automated Molecular Biology Platform for Unknown Pathogen Detection
Kamlesh D. Patel, Ph.D., Principal Member, Technical Staff, Biosystems Research Group, Sandia National Laboratories
Release Date: Apr 28, 2012
Challenges Inherent in Designing and Analyzing Experiments Using NGS
Ghia Euskirchen, Ph.D., Director of DNA Sequencing Program, Center for Genomics & Personalized Medicine, Stanford University School of Medicine
Release Date: Apr 27, 2012